PARP1 inhibition has initially been proposed as a therapeutic strategy in Ewing sarcoma, subsequent to the identification of an interaction between PARP1 and the fusion transcripts that potentiated DNA damage (55). Here, PARP1 is linked to Ewing sarcoma.